Editors:
- This book will focus on recently developed targeted therapies other than monoclonal antibodies used in lymphoma patients, both in routine practice and investigative trials
- Divided by groups of drugs, the book will revisit the most relevant aspects of these targeted therapies with special emphasis on molecular mechanisms and clinical effects of resistance
- The book features a diverse array of internationally recognized experts
Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 17)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (6 chapters)
-
Front Matter
-
Back Matter
About this book
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
Editors and Affiliations
-
Department of Onco-Hematology, Unit of Lymphoid Malignancies, IRCCS San Raffaele Scientific Institute, Milan, Italy
Andrés J. M. Ferreri
About the editor
Andrés J. M. Ferreri has a degree in Medicine from the Facultad de Medicina of the Universidad de Buenos Aires, Argentina (1985), and obtained the degree of Doctor in Medicine and Surgery in the Facoltà di Medicina e Chirurgia dell’Università degli Studi di Parma, Italy, in 1992. He is a Specialist in Clinical Oncology (Università degli Studi di Milan, Italy, 2005). He was a research fellow at the Divisione di Oncologia Sperimentale “E” and at the Divisione di Oncologia Médica “A” of the Istituto Nazionale dei Tumori of Milan (1989–1994) and vice-director of the Medical Oncology Unit of the San Raffaele Scientific Institute of Milan, Italy. Currently, Dr. Ferreri is Head of the Unit of Lymphoid Malignancies of the San Raffaele Scientific Institute of Milan, and is a Contract Professor of Oncology in the Vita e Salute University, Milan. He is fully devoted to the research on non-Hodgkin lymphomas and is an opinion leader in the field of extranodal lymphomas. Dr. Ferreri is Associate Editor of the ESO/START Project and of “Haematological Oncology” and Faculty of the European School of Oncology. Dr. Ferreri is a member of EHA, ESMO, ASH, and ASCO.
Bibliographic Information
Book Title: Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
Editors: Andrés J. M. Ferreri
Series Title: Resistance to Targeted Anti-Cancer Therapeutics
DOI: https://doi.org/10.1007/978-3-319-75184-9
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer International Publishing AG, part of Springer Nature 2018
Hardcover ISBN: 978-3-319-75183-2Published: 13 April 2018
Softcover ISBN: 978-3-030-09165-1Published: 26 January 2019
eBook ISBN: 978-3-319-75184-9Published: 04 April 2018
Series ISSN: 2196-5501
Series E-ISSN: 2196-551X
Edition Number: 1
Number of Pages: XIII, 138
Number of Illustrations: 1 b/w illustrations, 13 illustrations in colour
Topics: Cancer Research, Molecular Medicine